[
  {
    "abstract_id": "EASD-2026-OP-051",
    "title": "CagriSema 2.4mg/2.4mg in obesity without diabetes — Phase 3 REDEFINE-mock readout",
    "authors": "Mock P, Mock Q",
    "abstract_text": "CagriSema (cagrilintide+semaglutide) achieved -17.3% placebo-adjusted body weight at 68 weeks in a synthetic Phase 3 obesity cohort. GI AE 29.8%. All numerical values are mock and not from any real trial.",
    "phase": "Phase 3",
    "weight_loss_pct": 17.3,
    "gi_ae_pct": 29.8
  },
  {
    "abstract_id": "EASD-2026-OP-052",
    "title": "Amycretin once weekly subcutaneous — Phase 1b in obesity (mock data)",
    "authors": "Mock R, Mock S",
    "abstract_text": "Amycretin (NN9487) demonstrated mean placebo-adjusted weight loss of -11.5% over 36 weeks in a Phase 1b synthetic cohort. GI AE 18.4%. All data synthetic.",
    "phase": "Phase 1b",
    "weight_loss_pct": 11.5,
    "gi_ae_pct": 18.4
  },
  {
    "abstract_id": "EASD-2026-OP-088",
    "title": "Mazdutide GLP-1/glucagon dual in Chinese obesity cohort — Phase 3 (synthetic)",
    "authors": "Mock T, Mock U",
    "abstract_text": "Mazdutide (IBI362) showed -12.6% placebo-adjusted weight loss at 48 weeks in a Phase 3 mock Chinese obesity population. GI AE 26.0%. Mock data; not clinically validated.",
    "phase": "Phase 3",
    "weight_loss_pct": 12.6,
    "gi_ae_pct": 26.0
  },
  {
    "abstract_id": "EASD-2026-PO-104",
    "title": "Pemvidutide in MASH-obesity overlap — Phase 2 hepatic + weight outcomes (mock)",
    "authors": "Mock V",
    "abstract_text": "Pemvidutide (ALT-801), a GLP-1/glucagon dual agonist, produced -9.8% placebo-adjusted weight loss at 24 weeks in a synthetic Phase 2 MASH-obesity overlap cohort. GI AE 25.4%. Synthetic data only.",
    "phase": "Phase 2",
    "weight_loss_pct": 9.8,
    "gi_ae_pct": 25.4
  },
  {
    "abstract_id": "EASD-2026-PO-105",
    "title": "Petrelintide amylin analog — Phase 1b first-in-human in obesity (synthetic)",
    "authors": "Mock W",
    "abstract_text": "Petrelintide (ZP8396), a long-acting amylin analog, achieved -8.2% mean weight loss at 16 weeks in Phase 1b mock obesity cohort. GI AE 13.7%. Mock data.",
    "phase": "Phase 1b",
    "weight_loss_pct": 8.2,
    "gi_ae_pct": 13.7
  },
  {
    "abstract_id": "EASD-2026-PO-118",
    "title": "Ecnoglutide weekly subcutaneous in obesity — Phase 2 dose escalation (mock)",
    "authors": "Mock X, Mock Y",
    "abstract_text": "Ecnoglutide (XW003), a long-acting GLP-1 analog, achieved -10.4% placebo-adjusted weight loss at 26 weeks in a synthetic Phase 2 obesity cohort. GI AE 21.0%. All data mock.",
    "phase": "Phase 2",
    "weight_loss_pct": 10.4,
    "gi_ae_pct": 21.0
  }
]